Li D, Tan R, Hernandez S, Reilly N, Bussberg C, Mansfield C. Patient preferences for unresectable hepatocellular carcinoma treatments: a discrete-choice experiment. Cancers. 2023 Feb 25;15(5):1470. doi: 10.3390/cancers15051470
Dong OM. Using the diffusion of innovation theory to understand the challenges and opportunities to advancing use of nutrigenetics in clinical practice. Lifestyle Genom. 2021 Dec;14(4):124-8. doi: 10.1159/000517760
Wilson M, Lucas A, Cameron A, Luo M. Budget impact of adding vedolizumab to a health plan formulary as a first-line biologic option for ulcerative colitis and crohn's disease. Am Health Drug Benefits. 2018 Jul;11(5):253-62.
Zeisel SH, Niculescu MD, Meyer KA, Dong OM, Chmurzynska A, Kohlmeier M. Precision nutrition. A nutrigenetic-based framework to establish guidelines for choline intake. Presented at the 2019 Congress of the International Society of Nutrigenetics & Nutrigenomics; July 13, 2019. Cambridge, United Kingdom. [abstract] Lifestyle Genom. 2018; 11:178. doi: 10.1159/000501177
Dong OM. Pharmaconutrigenetics of antipsychotic-induced weight gain. Presented at the Congress of the International Society of Nutrigenetics & Nutrigenomics; July 12, 2019. Cambridge, UK. [abstract] Lifestyle Genom. 2018; 11.
Harris JB, Ward MA, Schwab P. Is response-guided therapy being applied in the clinical setting? The hepatitis C example. Am Health Drug Benefits. 2015 Feb;8(1):22-8.
Sacco P, Capkun-Niggli G, Zhang X, Jose R. The economic burden of fragile x syndrome: healthcare resource utilization in the United States. Am Health Drug Benefits. 2013 Mar;6(2):73-83.
Lennert B, Bibeau W, Farrelly E, Sacco P, Schoor T. Assessment of treatment patterns and patient outcomes in levodopa-induced dyskinesias (ASTROID): a US chart review study. Am Health Drug Benefits. 2012 Sep;5(6):347-58.